The SAIR database is designed to help scientists train AI models to better predict protein-ligand binding affinities for drug ...

Modifications in proteins after they are synthesized (post-translational) are changes that play a fundamental role in cell ...

Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen ...

Donanemab In May of 2023, two months prior to the full approval of lecanemab, another promising treatment for the disease, Eli Lilly’s donanemab, emerged from Phase III trials.

Donanemab and Lecanemab have been hailed as breakthrough treatments for slowing down the symptoms of early-stage Alzheimer's, the most common type of dementia. They are active substances used to ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. They represent a huge step forward in research because they target a known cause of the ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. They represent a huge step forward in research because they target a known cause of the disease, ...

Researchers used advanced microscopy to uncover important protein structures. For the first time, two important protein ...